---
schema_version: "secwatch.filing_event.v1"
accession: "0001937653-23-000036"
form_type: "8-K"
ticker: "ZYME"
cik: "0001937653"
company_name: "Zymeworks Inc."
filed_at: "2023-11-07T23:59:59+00:00"
generated_at: "2026-06-08T17:49:18.596904+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Zymeworks reports 44% reduction in nine-month net loss to $104.2M; launches ZW251 IND candidate for HCC

## Summary
- Nine-month net loss decreased 44% to $104.2M vs $185.1M same period 2022; revenue up 491% to $59.1M.
- Cash resources $390.2M as of Sept 30, 2023; expected to fund operations through at least end of 2026.
- ZW251, GPC3-targeted ADC for hepatocellular carcinoma, nominated as next IND candidate; filing expected 2H-2025.
- Zanidatamab partner BeiGene presented Phase 1b/2 data: ORR 75.8%, mDOR 22.8 months, mPFS 16.7 months in first-line HER2+ GEA.
- Termination of licensing agreement for zanidatamab zovodotin with BeiGene; Zymeworks regained APAC rights and plans Phase 2 study in NSCLC.

## SEC filing metadata
- accession: 0001937653-23-000036
- form_type: 8-K
- ticker: ZYME
- cik: 0001937653
- company_name: Zymeworks Inc.
- filed_at: 2023-11-07T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1937653/000193765323000036/0001937653-23-000036-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1937653/000193765323000036/zyme-20231107.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001937653-23-000036
- JSON: https://secwatch.observer/filing/0001937653-23-000036.json
- Plain text: https://secwatch.observer/filing/0001937653-23-000036.txt

## Key facts
- Earnings Releases
  Zymeworks Inc. reported financial results for third quarter 2023.
  - Period: third quarter 2023
  - Result: reported results
  source text: On November 7, 2023 , Zymeworks Inc. (the “Company”) issued a press release announcing its financial results for the fiscal quarter ended September 30, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1937653/000193765323000036/0001937653-23-000036-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.